Search

Your search keyword '"Daemen, Toos"' showing total 401 results
Start Over Author "Daemen, Toos"
401 results on '"Daemen, Toos"'

7. Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy.

Author

Bhatt, Darshak K. and Daemen, Toos

Subjects
*ONCOLYTIC virotherapy, *DETECTOR circuits, *IMMUNE response, *VIRAL DNA, *PATTERN perception receptors, *T cell receptors
Abstract

Oncolytic virotherapy is a promising immunotherapy approach for cancer treatment that utilizes viruses to preferentially infect and eliminate cancer cells while stimulating the immune response. In this review, we synthesize the current literature on the molecular circuits of immune sensing and response to oncolytic virotherapy, focusing on viral DNA or RNA sensing by infected cells, cytokine and danger-associated-signal sensing by neighboring cells, and the subsequent downstream activation of immune pathways. These sequential sense-and-response mechanisms involve the triggering of molecular sensors by viruses or infected cells to activate transcription factors and related genes for a breadth of immune responses. We describe how the molecular signals induced in the tumor upon virotherapy can trigger diverse immune signaling pathways, activating both antigen-presenting-cell-based innate and T cell-based adaptive immune responses. Insights into these complex mechanisms provide valuable knowledge for enhancing oncolytic virotherapy strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Supplementary Methods from Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer

Author

Wouters, Maartje C.A., primary, Komdeur, Fenne L., primary, Workel, Hagma H., primary, Klip, Harry G., primary, Plat, Annechien, primary, Kooi, Neeltje M., primary, Wisman, G. Bea A., primary, Mourits, Marian J.E., primary, Arts, Henriette J.G., primary, Oonk, Maaike H.M., primary, Yigit, Refika, primary, de Jong, Steven, primary, Melief, Cornelis J.M., primary, Hollema, Harry, primary, Duiker, Evelien W., primary, Daemen, Toos, primary, de Bruyn, Marco, primary, and Nijman, Hans W., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure S1 from Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer

Author

Wouters, Maartje C.A., primary, Komdeur, Fenne L., primary, Workel, Hagma H., primary, Klip, Harry G., primary, Plat, Annechien, primary, Kooi, Neeltje M., primary, Wisman, G. Bea A., primary, Mourits, Marian J.E., primary, Arts, Henriette J.G., primary, Oonk, Maaike H.M., primary, Yigit, Refika, primary, de Jong, Steven, primary, Melief, Cornelis J.M., primary, Hollema, Harry, primary, Duiker, Evelien W., primary, Daemen, Toos, primary, de Bruyn, Marco, primary, and Nijman, Hans W., primary

Published
2023
Full Text
View/download PDF

15. Data from Treatment Regimen, Surgical Outcome, and T-cell Differentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer

Author

Wouters, Maartje C.A., primary, Komdeur, Fenne L., primary, Workel, Hagma H., primary, Klip, Harry G., primary, Plat, Annechien, primary, Kooi, Neeltje M., primary, Wisman, G. Bea A., primary, Mourits, Marian J.E., primary, Arts, Henriette J.G., primary, Oonk, Maaike H.M., primary, Yigit, Refika, primary, de Jong, Steven, primary, Melief, Cornelis J.M., primary, Hollema, Harry, primary, Duiker, Evelien W., primary, Daemen, Toos, primary, de Bruyn, Marco, primary, and Nijman, Hans W., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Materials from Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response

Author

van Poelgeest, Mariëtte I.E., primary, Welters, Marij J.P., primary, Vermeij, Renee, primary, Stynenbosch, Linda F.M., primary, Loof, Nikki M., primary, Berends-van der Meer, Dorien M.A., primary, Löwik, Margriet J.G., primary, Hamming, Ineke L.E., primary, van Esch, Edith M.G., primary, Hellebrekers, Bart W.J., primary, van Beurden, Marc, primary, Schreuder, Henk W., primary, Kagie, Marjolein J., primary, Trimbos, J. Baptist M.Z., primary, Fathers, Lorraine M., primary, Daemen, Toos, primary, Hollema, Harry, primary, Valentijn, A. Rob P.M., primary, Oostendorp, Jaap, primary, Oude Elberink, J. Hanneke N.G., primary, Fleuren, Gertjan J., primary, Bosse, Tjalling, primary, Kenter, Gemma G., primary, Stijnen, Theo, primary, Nijman, Hans W., primary, Melief, Cornelis J.M., primary, and van der Burg, Sjoerd H., primary

Published
2023
Full Text
View/download PDF

26. HLA Class I Alleles and Cervical Neoplasia

Author

Visser, Jeroen T. J., Hoogeboom, Baukje Nynke, Reesink-Peters, Nathalie, Klip, Harry, Hepkema, Bouke, van Velde, Hans, van der Zee, Ate G. J., and Daemen, Toos

Published
2003

31. Strategies to Target Tumor Immunosuppression

Author

Rezaei, Nima, Koutsoumpli, Georgia, Draghiciu, Oana, Nijman, Hans W., Oyarce, Cesar, Daemen, Toos, Rezaei, Nima, Koutsoumpli, Georgia, Draghiciu, Oana, Nijman, Hans W., Oyarce, Cesar, and Daemen, Toos

Abstract

The tumor microenvironment is currently in the spotlight of cancer immunology research as a key factor impacting tumor development and progression. While antigen-specific immune responses play a crucial role in tumor rejection, the tumor hampers these immune responses by creating an immunosuppressive microenvironment. Recently, major progress has been achieved in the field of cancer immunotherapy, and several groundbreaking clinical trials demonstrated the potency of such therapeutic interventions in patients. Yet, the responses greatly vary among individuals. This calls for the rational design of more efficacious cancer immunotherapeutic interventions that take into consideration the “immune signature” of the tumor. Multimodality treatment regimens that aim to enhance intratumoral homing and activation of antigen-specific immune effector cells, while simultaneously targeting tumor immunosuppression, are pivotal for potent antitumor immunity.

Published
2021

35. Strategies to Target Tumor Immunosuppression

Author

Koutsoumpli, Georgia, Draghiciu, Oana, Nijman, Hans W., Oyarce, Cesar, Daemen, Toos, Rezaei, Nima, Targeted Gynaecologic Oncology (TARGON), Translational Immunology Groningen (TRIGR), and Microbes in Health and Disease (MHD)

Subjects
Tumor microenvironment, Antitumor immunity, Cytokine Therapy, business.industry, medicine.medical_treatment, education, Immunosuppression, macromolecular substances, humanities, Tumor immunosuppression, Clinical trial, medicine, Cancer research, Endothelin receptor, business, Antibody therapy
Abstract

Several strategies, aimed at activating both innate and adaptive antitumor immunity, have been and are currently evaluated in clinical trials. In separate chapters of this book, these strategies are being reviewed and discussed. An alternative option is to (also) target intratumoral immune escape mechanisms in order to enhance intratumoral antitumor responses. Based on their overall target aim, these strategies can be divided into two main categories: Strategies that aim at enhancing intratumor homing of effector T cells and strategies to maintain the activity of these cells once they have reached the tumor site. Currently used therapeutic strategies that attempt to increase homing of effector T cells to tumors are local tumor irradiation, blockade of endothelin receptors, and taxane-based chemotherapy. Strategies that aim to enhance antitumor activity of intratumor effector T cells, either by overcoming tumor-induced tolerance or by overriding the immunosuppressive mechanisms imposed during tumor development, are depletion or functional inhibition of immunosuppressive populations, blockade of negative regulatory factors, and blockade of tumor growth factor-beta (TGF-β)-induced signaling.

Published
2020

36. First-in-Human Phase I Clinical Trial of an SFV-Based RNA Replicon Cancer Vaccine against HPV-Induced Cancers

Author

Komdeur, Fenne L., primary, Singh, Amrita, additional, van de Wall, Stephanie, additional, Meulenberg, Janneke J.M., additional, Boerma, Annemarie, additional, Hoogeboom, Baukje Nynke, additional, Paijens, Sterre T., additional, Oyarce, Cesar, additional, de Bruyn, Marco, additional, Schuuring, Ed, additional, Regts, Joke, additional, Marra, Ruben, additional, Werner, Naomi, additional, Sluis, Jessica, additional, van der Zee, Ate G.J., additional, Wilschut, Jan C., additional, Allersma, Derk P., additional, van Zanten, Coba J., additional, Kosterink, Jos G.W., additional, Jorritsma-Smit, Annelies, additional, Yigit, Refika, additional, Nijman, Hans W., additional, and Daemen, Toos, additional

Published
2021
Full Text
View/download PDF

46. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial

Author

Leffers, Ninke, Lambeck, Annechien J.A., Gooden, Marloes J.M., Hoogeboom, Baukje-Nynke, Wolf, Rinze, Hamming, Ineke E., Hepkema, Bouke G., Willemse, Pax H.B., Molmans, Barbara H.W., Hollema, Harry, Drijfhout, Jan W., Sluiter, Willem J., Valentijn, Rob A. P.M., Fathers, Loraine M., Oostendorp, Jaap, van der Zee, Ate G.J., Melief, Cornelis J., van der Burg, Sjoerd H., Daemen, Toos, and Nijman, Hans W.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results